AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32423402 — intervention group
Group type: COMPARATOR
Intervention: Social withdrawal behaviors (ADBB)
Number of subjects: 158
Study 32423455 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate and cytosine arabinoside (MA)
Number of subjects: 36
Study 32423456 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.55 T CMR imaging
Number of subjects: 65
Study 32423456 — intervention group
Group type: COMPARATOR
Intervention: 1.5 T CMR imaging
Number of subjects: 65
Study 32423477 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy with epirubicin/docetaxel for 6 cycles, supplemented with bevacizumab in cycles 3-6
Number of subjects: 104
Study 32423477 — intervention group
Group type: EXPERIMENTAL
Intervention: Cell-loss metric based on serum thymidine kinase 1 (sTK1) levels
Number of subjects: 104
Study 32423477 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumour volume measurement
Number of subjects: 104
Study 32423837 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200mg intravenously every 3 weeks until confirmed progression, intolerable toxicity, patient withdrawal, or 24 months of therapy.
Number of subjects: 678
Study 32423904 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep apnoea group (defined as apnoea-hypopnoea index ≥15 events per hour)
Number of subjects: 1007
Study 32423904 — intervention group
Group type: COMPARATOR
Intervention: Non-sleep apnoea group
Number of subjects: 1007
Study 32423904 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep apnoea group
Number of subjects: 1007
Study 32423938 — intervention group
Group type: EXPERIMENTAL
Intervention: Red blood cell transfusion
Number of subjects: 0
Study 32424011 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepping Stones and Creating Futures (SS-CF) trial
Number of subjects: 1913
Study 32424011 — intervention group
Group type: EXPERIMENTAL
Intervention: CHANGE trial
Number of subjects: 1913
Study 32424011 — intervention group
Group type: EXPERIMENTAL
Intervention: Indashyikirwa
Number of subjects: 1913
Study 32424028 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimalarial treatment
Number of subjects: 0
Study 32424028 — intervention group
Group type: COMPARATOR
Intervention: Control group (no antimalarial treatment)
Number of subjects: 0
Study 32424516 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen Reserve Index monitoring
Number of subjects: 0
Study 32424516 — intervention group
Group type: COMPARATOR
Intervention: Standard monitoring
Number of subjects: 0
Study 32424535 — intervention group
Group type: EXPERIMENTAL
Intervention: NAC-treated graft (N-acetylcysteine enriched tumescent fluid)
Number of subjects: 15
Study 32424535 — intervention group
Group type: COMPARATOR
Intervention: Control graft (standard tumescent fluid)
Number of subjects: 15
Study 32425736 — intervention group
Group type: EXPERIMENTAL
Intervention: GBCK25 (500 mg/day)
Number of subjects: 90
Study 32425736 — intervention group
Group type: EXPERIMENTAL
Intervention: GBCK25 (125 mg/day)
Number of subjects: 90
Study 32425736 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 32425802 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimavanserin 34 mg/day
Number of subjects: 40
Study 32425873 — intervention group
Group type: EXPERIMENTAL
Intervention: iPad-Based App (Neolexon®)
Number of subjects: 0
Study 32425873 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 32425926 — intervention group
Group type: EXPERIMENTAL
Intervention: T cell-based immunotherapy targeting alpha-fetoprotein (AFP)
Number of subjects: 0
Study 32426038 — intervention group
Group type: EXPERIMENTAL
Intervention: Eculizumab
Number of subjects: 0
Study 32426038 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 32426039 — intervention group
Group type: EXPERIMENTAL
Intervention: DMF 240 mg twice daily (BID)
Number of subjects: 1736
Study 32426039 — intervention group
Group type: COMPARATOR
Intervention: PBO/DMF (placebo for years 0-2 / DMF for years 3-9)
Number of subjects: 1736
Study 32426039 — intervention group
Group type: EXPERIMENTAL
Intervention: DMF/DMF
Number of subjects: 1736
Study 32426039 — intervention group
Group type: COMPARATOR
Intervention: PBO/DMF
Number of subjects: 1736
Study 32426039 — intervention group
Group type: EXPERIMENTAL
Intervention: DMF
Number of subjects: 1736
Study 32426103 — intervention group
Group type: EXPERIMENTAL
Intervention: Phosphatidylcholine (PC)
Number of subjects: 0
Study 32426103 — intervention group
Group type: EXPERIMENTAL
Intervention: Sphingomyelin (SM)
Number of subjects: 0
Study 32426103 — intervention group
Group type: EXPERIMENTAL
Intervention: Acylcarnitine metabolomes
Number of subjects: 0
Study 32426158 — intervention group
Group type: EXPERIMENTAL
Intervention: IDEAs (Improving Diabetes Eye screening Attendance) intervention delivered in general practice.
Number of subjects: 8
Study 32426158 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care in general practice).
Number of subjects: 8
Study 32426309 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 32426409 — intervention group
Group type: EXPERIMENTAL
Intervention: Early Controlled Motion (ECM) - ankle movements 5 times a day from weeks 3 to 8 after rupture
Number of subjects: 130
Study 32426409 — intervention group
Group type: COMPARATOR
Intervention: Immobilization (IM) - immobilized for 8 weeks
Number of subjects: 130
Study 32426530 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Neonatal Temperature Monitor (NTM)
Number of subjects: 39
Study 32426530 — intervention group
Group type: COMPARATOR
Intervention: Philips Intellivue MP30 Patient Monitor
Number of subjects: 39
Study 32426530 — intervention group
Group type: COMPARATOR
Intervention: Axillary thermometer
Number of subjects: 39
Study 32427039 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolated atrial septal defect (n=34)
Number of subjects: 66
Study 32427039 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolated ventricular septal defect (n=32)
Number of subjects: 66
Study 32427039 — intervention group
Group type: COMPARATOR
Intervention: Healthy matched peers (n=40)
Number of subjects: 66
Study 32427279 — intervention group
Group type: EXPERIMENTAL
Intervention: Early corticosteroid (methylprednisolone 0.5 to 1 mg/kg/day for 3 days)
Number of subjects: 213
Study 32427279 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SOC)
Number of subjects: 213
Study 32427279 — intervention group
Group type: EXPERIMENTAL
Intervention: Early corticosteroid
Number of subjects: 213
Study 32427581 — intervention group
Group type: EXPERIMENTAL
Intervention: IgG antibodies against CIDRα1.7 and CIDRα1.8
Number of subjects: 0
Study 32427581 — intervention group
Group type: EXPERIMENTAL
Intervention: IgG antibodies against CIDRγ3
Number of subjects: 0
Study 32427579 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab (anti-PD-L1 therapy)
Number of subjects: 0
Study 32427579 — intervention group
Group type: COMPARATOR
Intervention: Anti-PD-1 therapy
Number of subjects: 0
Study 32428300 — intervention group
Group type: EXPERIMENTAL
Intervention: Reducing saturated fat intake
Number of subjects: 59000
Study 32428369 — intervention group
Group type: EXPERIMENTAL
Intervention: Susceptibility-guided therapy (14-day triple or quadruple therapy based on susceptibility to clarithromycin, levofloxacin, and metronidazole)
Number of subjects: 112
Study 32428369 — intervention group
Group type: EXPERIMENTAL
Intervention: All regimens of susceptibility-guided therapy
Number of subjects: 112
Study 32428369 — intervention group
Group type: EXPERIMENTAL
Intervention: Susceptibility-guided therapy
Number of subjects: 112
Study 32428369 — intervention group
Group type: COMPARATOR
Intervention: Empiric classical bismuth quadruple therapy
Number of subjects: 112
Study 32428543 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitric Oxide-Releasing Topical Medication
Number of subjects: 0
Study 32428543 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 32429000 — intervention group
Group type: EXPERIMENTAL
Intervention: Gepotidacin 750 mg IV over 2 hours
Number of subjects: 0
Study 32429847 — intervention group
Group type: EXPERIMENTAL
Intervention: Subretinal drusenoid deposits and drusen
Number of subjects: 480
Study 32429847 — intervention group
Group type: EXPERIMENTAL
Intervention: RPE cell bodies
Number of subjects: 480
Study 32429847 — intervention group
Group type: EXPERIMENTAL
Intervention: Choriocapillaris' vascular density
Number of subjects: 480
Study 32429877 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated services for depression and NCDs
Number of subjects: 20
Study 32429877 — intervention group
Group type: EXPERIMENTAL
Intervention: Provider communication strategies
Number of subjects: 20
Study 32429877 — intervention group
Group type: EXPERIMENTAL
Intervention: Training for providers
Number of subjects: 20
Study 32429879 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based couple testing during pregnancy
Number of subjects: 21
Study 32429923 — intervention group
Group type: COMPARATOR
Intervention: Untreated lead-in period (4 months)
Number of subjects: 19
Study 32429923 — intervention group
Group type: COMPARATOR
Intervention: 4-stair climb timed function measure
Number of subjects: 19
Study 32429923 — intervention group
Group type: COMPARATOR
Intervention: Whole-body MRI and DEXA estimates
Number of subjects: 19
Study 32429929 — intervention group
Group type: EXPERIMENTAL
Intervention: NAC
Number of subjects: 24
Study 32429939 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-delivered cognitive behavioral therapy for BDD
Number of subjects: 88
Study 32429963 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective neural electrical stimulation of radial and median nerves using multicontact cuff electrodes.
Number of subjects: 8
Study 32429967 — intervention group
Group type: EXPERIMENTAL
Intervention: lenalidomide combined with dexamethasone
Number of subjects: 41
Study 32430018 — intervention group
Group type: EXPERIMENTAL
Intervention: Chia supplementation (25 g/day)
Number of subjects: 25
Study 32430019 — intervention group
Group type: EXPERIMENTAL
Intervention: FACT-M questionnaire in treatment-naïve patients (Part B)
Number of subjects: 172
Study 32430019 — intervention group
Group type: EXPERIMENTAL
Intervention: FACT-M questionnaire in previously treated patients (Part A)
Number of subjects: 172
Study 32430019 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined FACT-M data from Part A and Part B
Number of subjects: 172
Study 32430019 — intervention group
Group type: COMPARATOR
Intervention: ECOG performance status 0 versus 1
Number of subjects: 172
Study 32430019 — intervention group
Group type: COMPARATOR
Intervention: EQ-5D items
Number of subjects: 172
Study 32430019 — intervention group
Group type: COMPARATOR
Intervention: Cronbach's α
Number of subjects: 172
Study 32430047 — intervention group
Group type: EXPERIMENTAL
Intervention: BetterBack Model of Care implementation
Number of subjects: 116
Study 32430177 — intervention group
Group type: EXPERIMENTAL
Intervention: rAAV-G6PC-S298C vector
Number of subjects: 0
Study 32430395 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous alteplase (0.9 mg/kg of body weight)
Number of subjects: 821
Study 32430395 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 821
Study 32430412 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplementation
Number of subjects: 0
Study 32430412 — intervention group
Group type: COMPARATOR
Intervention: Control group (no iron supplementation)
Number of subjects: 0
Study 32430414 — intervention group
Group type: EXPERIMENTAL
Intervention: Extrafine triple therapy
Number of subjects: 0
Study 32430416 — intervention group
Group type: EXPERIMENTAL
Intervention: Home telemonitoring of variability in forced oscillation technique (FOT) measures
Number of subjects: 15
Study 32430416 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily FOT parameters (resistance (R) and reactance (X))
Number of subjects: 15
Study 32430415 — intervention group
Group type: EXPERIMENTAL
Intervention: Microbiome-based therapies; details on dosage and duration not available.
Number of subjects: 0
Study 32430415 — intervention group
Group type: EXPERIMENTAL
Intervention: Host-targeted therapeutics; details on dosage and duration not available.
Number of subjects: 0
Study 32430445 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient decision aid
Number of subjects: 772
Study 32430445 — intervention group
Group type: COMPARATOR
Intervention: Traditional booklet (Control)
Number of subjects: 772
Study 32430583 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic polyglutamate tablets (oral) and 500 mL of a 10% mannitol solution (intravenous) before the injection of 3.7-5.5 GBq of radioligand therapy (RLT)
Number of subjects: 43
Study 32430583 — intervention group
Group type: EXPERIMENTAL
Intervention: Radioligand therapy (RLT) with 3.7-5.5 GBq
Number of subjects: 43
Study 32430583 — intervention group
Group type: EXPERIMENTAL
Intervention: Dosimetry measurements
Number of subjects: 43
Study 32430709 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 g OGTT
Number of subjects: 100
Study 32430709 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 100
Study 32430709 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 g OGTT
Number of subjects: 100
Study 32431021 — intervention group
Group type: EXPERIMENTAL
Intervention: V-LAP™ device
Number of subjects: 0
Study 32431658 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation (tDCS) paired with aerobic exercise (2.5 mA for 20 minutes)
Number of subjects: 17
Study 32431658 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS paired with aerobic exercise
Number of subjects: 17
Study 32431667 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (3 mg/day)
Number of subjects: 0
Study 32431698 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-volume high-intensity interval exercise training (HIIT) for 10 weeks, 3 sessions/week, consisting of ten 60 s intervals of low intensity (50-60% HRR) and high intensity (80-90% HRR)
Number of subjects: 10
Study 32432123 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal Fosfomycin, Metronidazole, and Molgramostim
Number of subjects: 0
Study 32432123 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 32432489 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemtuzumab ozogamicin (GO) as monotherapy for R/R AML
Number of subjects: 331
Study 32432839 — intervention group
Group type: EXPERIMENTAL
Intervention: MitraClip
Number of subjects: 86
Study 32433094 — intervention group
Group type: EXPERIMENTAL
Intervention: iStent inject devices
Number of subjects: 42
Study 32433237 — intervention group
Group type: EXPERIMENTAL
Intervention: Islet cell grafts cultured for ≥96 hours
Number of subjects: 40
Study 32433600 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant modified FOLFIRINOX (mFOLFIRINOX)
Number of subjects: 44
Study 32433647 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolite changes in fasting plasma samples among women with incident T2D
Number of subjects: 173
Study 32433647 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline metabolic profile
Number of subjects: 173
Study 32433647 — intervention group
Group type: EXPERIMENTAL
Intervention: Longitudinal analysis of metabolic changes
Number of subjects: 173
Study 32433647 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathway analysis
Number of subjects: 173
Study 32433647 — intervention group
Group type: EXPERIMENTAL
Intervention: Longitudinal analyses
Number of subjects: 173
Study 32433728 — intervention group
Group type: EXPERIMENTAL
Intervention: Homozygous hemoglobin E variant (Hb EE)
Number of subjects: 515
Study 32433728 — intervention group
Group type: COMPARATOR
Intervention: Normal hemoglobin AA genotype
Number of subjects: 515
Study 32433768 — intervention group
Group type: EXPERIMENTAL
Intervention: Dreem headband (DH)
Number of subjects: 25
Study 32433768 — intervention group
Group type: COMPARATOR
Intervention: Polysomnography (PSG)
Number of subjects: 25
Study 32433821 — intervention group
Group type: EXPERIMENTAL
Intervention: Amplatzer Piccolo Occluder
Number of subjects: 200
Study 32433894 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactive patients
Number of subjects: 1946
Study 32433894 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly active patients
Number of subjects: 1946
Study 32433894 — intervention group
Group type: COMPARATOR
Intervention: Active patients
Number of subjects: 1946
Study 32433993 — intervention group
Group type: EXPERIMENTAL
Intervention: WMFT-RPSS
Number of subjects: 29
Study 32434278 — intervention group
Group type: EXPERIMENTAL
Intervention: Vamorolone (VBP15)
Number of subjects: 0
Study 32434278 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 32434935 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran initiation within 3 months after the ischaemic stroke
Number of subjects: 1489
Study 32434935 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran initiation
Number of subjects: 1489
Study 32435020 — intervention group
Group type: EXPERIMENTAL
Intervention: C1 inhibitor (C1-INH) 1000U administered biweekly via intravenous infusion
Number of subjects: 8
Study 32435020 — intervention group
Group type: EXPERIMENTAL
Intervention: C1 inhibitor (C1-INH)
Number of subjects: 8
Study 32435762 — intervention group
Group type: EXPERIMENTAL
Intervention: Online education (OLE)
Number of subjects: 20
Study 32435762 — intervention group
Group type: EXPERIMENTAL
Intervention: Interprofessional education (IPE)
Number of subjects: 20
Study 32436060 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-06840003 (500 mg BID)
Number of subjects: 17
Study 32436060 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-06840003 (various doses)
Number of subjects: 17
Study 32436180 — intervention group
Group type: EXPERIMENTAL
Intervention: F-18 fluorocholine PET/CT
Number of subjects: 30
Study 32436180 — intervention group
Group type: COMPARATOR
Intervention: Tc-99m sestamibi
Number of subjects: 30
Study 32436180 — intervention group
Group type: COMPARATOR
Intervention: Neck ultrasound
Number of subjects: 30
Study 32436335 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir (400 mg/d) plus Daclatasvir with or without Ribavirin (1-1.2 g/d) for 12 weeks
Number of subjects: 0
Study 32436335 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir (400 mg/d) plus Daclatasvir with or without Ribavirin (1-1.2 g/d) for 24 weeks
Number of subjects: 0
Study 32436335 — intervention group
Group type: COMPARATOR
Intervention: Ribavirin addition
Number of subjects: 0
Study 32436335 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir/Daclatasvir with or without Ribavirin
Number of subjects: 0
Study 32436724 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief interval exercise training (IET) intervention
Number of subjects: 0
Study 32436724 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 32436923 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation of a risk-management framework for incorporating stromal tumor-infiltrating lymphocytes (sTILs) in clinical trials.
Number of subjects: 0
Study 32436923 — intervention group
Group type: EXPERIMENTAL
Intervention: sTILs as an integral biomarker in a single-center phase II immunotherapy trial (TONIC trial, NCT02499367).
Number of subjects: 0
Study 32437328 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored mHealth support intervention for physical activity (PA)
Number of subjects: 60
Study 32437328 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 60
Study 32437423 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimized nutrition protocol (Group 2)
Number of subjects: 158
Study 32437423 — intervention group
Group type: COMPARATOR
Intervention: Standard nutrition protocol (Group 1)
Number of subjects: 158
Study 32437557 — intervention group
Group type: EXPERIMENTAL
Intervention: dihydroartemisinin/piperaquine (4 mg/kg/day for 3 days)
Number of subjects: 60
Study 32437557 — intervention group
Group type: COMPARATOR
Intervention: artesunate monotherapy followed by dihydroartemisinin/piperaquine (4 mg/kg/day for 3 days)
Number of subjects: 60
Study 32437664 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (200 mg flat dose IV) + Trastuzumab (8 mg/kg loading dose IV) + chemotherapy
Number of subjects: 37
Study 32437664 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab + Trastuzumab + chemotherapy
Number of subjects: 37
Study 32437738 — intervention group
Group type: EXPERIMENTAL
Intervention: Midostaurin treatment
Number of subjects: 116
Study 32438272 — intervention group
Group type: EXPERIMENTAL
Intervention: SC-002
Number of subjects: 35
Study 32438338 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth intervention including health reminders and psychoeducational messaging plus clinical standard of care reminders.
Number of subjects: 54
Study 32438338 — intervention group
Group type: COMPARATOR
Intervention: Standard of care reminders only (mailed appointments and automated telephone calls).
Number of subjects: 54
Study 32438452 — intervention group
Group type: EXPERIMENTAL
Intervention: Eliglustat therapy
Number of subjects: 231
Study 32438917 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced mammography (CEM)
Number of subjects: 47
Study 32439432 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose capsaicin (0.01 mM) nasal spray
Number of subjects: 0
Study 32439432 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment for idiopathic rhinitis
Number of subjects: 0
Study 32439653 — intervention group
Group type: EXPERIMENTAL
Intervention: Bempegaldesleukin (NKTR-214) plus Nivolumab
Number of subjects: 38
Study 32439700 — intervention group
Group type: EXPERIMENTAL
Intervention: iNeo-Vac-P01 (neoantigen vaccine)
Number of subjects: 22
Study 32439737 — intervention group
Group type: EXPERIMENTAL
Intervention: HbA1c assessment for diabetes mellitus (DM) and prediabetes (pre-DM) diagnosis
Number of subjects: 992
Study 32439737 — intervention group
Group type: EXPERIMENTAL
Intervention: HbA1c assessment in patients aged 50-59 years
Number of subjects: 992
Study 32439737 — intervention group
Group type: EXPERIMENTAL
Intervention: HbA1c assessment in patients aged ≥60 years
Number of subjects: 992
Study 32439737 — intervention group
Group type: EXPERIMENTAL
Intervention: HbA1c assessment in overweight patients
Number of subjects: 992
Study 32439737 — intervention group
Group type: EXPERIMENTAL
Intervention: HbA1c assessment in obese patients
Number of subjects: 992
Study 32439737 — intervention group
Group type: COMPARATOR
Intervention: HbA1c assessment in patients aged 18-29 years
Number of subjects: 992
Study 32439737 — intervention group
Group type: COMPARATOR
Intervention: HbA1c assessment in normal-weight patients
Number of subjects: 992